Latest News
-

HD Therapeutics Conference 2012 Updates: Day 1
Day 1 of our coverage of the Huntington's Disease Therapeutics Conference
-

Coming soon: HD Therapeutics Conference 2012
Huntington's Disease Therapeutics Conference starts next week. Twitter follow @HDBuzzfeed for live updates!
-

New analysis suggests 'small' CAG length doesn't matter after all
Size isn't everything: new research suggests that only a person's big CAG count, not the small one, affects HD onset
-

Special 'brain fat' injection helps HD mice
Directly injecting the brains of HD mice with a good type of fat called ganglioside GM1 provides dramatic benefit
-

HDYO! Huntington's Disease Youth Organization goes live
The Huntington's Disease Youth Organization website has just launched and its website is now active at www.hdyo.org
-

Could mesenchymal stem cells deliver gene silencing drugs?
Stem cells can deliver HD gene silencing drugs into cells in a dish. Do we need another delivery technology?
-

Double success for huntingtin RNAi gene silencing
2 bits of good news for RNAi gene silencing in HD: it's safe over six months, and a way to treat bigger brain areas
-

New experiments clarify the role of SIRT1 in HD – or do they?
Work from multiple labs suggests activating a protein called SIRT1 might help HD, but the picture is still confusing
-

Bone marrow transplantation in Huntington's Disease
Bone marrow transplant protects HD mice from some symptoms, suggesting the immune system may be an important target
-

2011 – a year in Huntington's disease research
Looking back at a year in Huntington's disease research – and the first year of HDBuzz
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Previously featured
-
Better Sleep, Better Function: New Study Links Sleep Quality to Clinical Outcomes in Huntington’s Disease
-
Keeping up with HD research just got easier: Introducing the HDBuzz Trial Tracker
-
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
-
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
-
Putting Huntington’s disease medications to the test: results from the Neuro-HD trial
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
